Bukwang announces effectiveness of Adipocell in IFATS 2008

Published: 2008-11-03 06:37:00

Updated: 2008-11-03 06:37:00

Bukwang said that Adipocell (allogenic adipose-derived stem cell) injection, which was developed by Anterogen, its affiliate company, is clinically effective in areas such as tissue repair and wound healing in Phase II and III studies which were conducted at Samsung Seoul Hospital between 2004 an...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK